Observational studyVirology journal2026
Pegylated interferon-α-2b add-on therapy to renal function for chronic hepatitis B patients who were treated with tenofovir disoproxil fumarate: a retrospective real-world study.
Observational study in Virology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLong-term tenofovir disoproxil fumarate (TDF) administration has been associated with potential adverse effects on renal function. Pegylated interferon-α2 (PEG-IFN-α2) therapy in chronic hepatitis B (CHB) patients increased estimated glomerular filtration rate (eGFR). Thus, the aim of this study was to analyze the influence of PEG-IFN-α-2b add-on to on-going TDF therapy in renal function in CHB patients.
methodsThis was a retrospective observational study. Ninety-one CHB patients who were treated with TDF for more than 48 weeks, had hepatitis B surface antigen (HBsAg) < 1500 IU/mL, and were hepatitis B e antigen-negative were recruited. Sixty-seven patients continued TDF monotherapy, and twenty-four patients received PEG-IFN-α-2b add-on therapy. Renal function indices were collected at baseline, 12 weeks, 24 weeks, and 48 weeks post-therapy. A linear mixed effects model for repeated measures was employed to analyze the associations between baseline information and serum β2-microglobulin (β2-MG)/urine α1-microglobulin (α1-MG) changes.
resultsHBsAg clearance rate was higher in TDF + PEG-IFN group compared with TDF monotherapy group (20.83% vs. 0.00%). There were no significant changes in blood urea nitrogen (BUN), creatinine (Cr), or eGFR in TDF monotherapy group. BUN and Cr was down-regulated, while eGFR was up-regulated at 48 weeks in TDF + PEG-IFN group. In TDF monotherapy group, serum β2-MG was elevated at 12, 24, and 48 weeks, whereas no significant changes were observed in TDF + PEG-IFN group. Serum β2-MG was higher in TDF monotherapy group than in TDF + PEG-IFN group. Urine α1-MG was increased in both groups at 48 weeks. TDF monotherapy was positive predictor for serum β2-MG increase, while TDF + PEG-IFN therapy negatively affect serum β2-MG level. Both TDF-based therapeutic strategies were positive predictors for urine α1-MG elevation.
conclusionPEG-IFN-α-2b might exert a protective effect against TDF-induced glomerular injury in CHB patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.